Evidence map›Paper›PMID 28882678›Full record

ArticleJournal of proteomics2018

RNA interference-mediated knockdown of SIRT1 and/or SIRT2 in melanoma: Identification of downstream targets by large-scale proteomics analysis.

Melissa J Wilking-Busch, Mary A Ndiaye, Xiaoqi Liu, Nihal Ahmad

Abstract read
In one paragraph

Article in Journal of proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Nicotinamide inhibits melanoma in vitro and in vivo.Journal of experimental & clinical cancer research : CR · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Melissa J Wilking-BuschDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Mary A NdiayeDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA.
Xiaoqi LiuDepartment of Biochemistry, Purdue University, 175 S. University Street, West Lafayette, IN, USA.
Nihal AhmadDepartment of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA; William S. Middleton VA Medical Center, 2500 Overlook Terrace, Madison, WI 53705, USA. Electronic address: nahmad@wisc.edu.

Funding

Role of Polo-Like Kinase-1 in Melanocytic TransformationR01AR059130 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2010 to 2019
$3.8M
Plk1 in Chemo-resistance of CancerR01CA157429 · NCI · UNIVERSITY OF KENTUCKY · PI XIAOQI LIU · 2011 to 2026
$3.5M
Improving chemotherapy of castration-resistant prostate cancer.R01CA196634 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2016 to 2025
$3.3M
Skin Diseases Research Center at the University of WisconsinP30AR066524 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI LONGLEY, B JACK · 2014 to 2018
$2.6M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Treatment of Castration-resistant Prostate Cancer (CRPC)R01CA196835 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2016 to 2020
$1.7M
Enhancing anti-neoplastic activity of metformin in prostate cancerR01CA192894 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2016 to 2020
$1.7M
Role of SIRT1 in melanocyte biology and melanocyte transformationR01CA176748 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AHMAD, NIHAL · 2013 to 2017
$1.6M
BLR&D Research Career Scientist Award ApplicationIK6BX003780 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI AHMAD, NIHAL · 2017 to 2021
–
Role of SIRT3 in melanoma development and progressionI01CX001441 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI AHMAD, NIHAL · 2017 to 2022
–
Plk1-Numb Cooperation in MelanomagenesisI01BX001008 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI AHMAD, NIHAL · 2013 to 2016
–
BLRD VA I01 BX001008BLRD VA IK6 BX003780CSRD VA I01 CX001441NCI NIH HHS R01 CA157429NCI NIH HHS R01 CA176748NCI NIH HHS R01 CA192894NCI NIH HHS R01 CA196634NCI NIH HHS R01 CA196835NCRR NIH HHS S10 RR029531NIAMS NIH HHS P30 AR066524NIAMS NIH HHS R01 AR059130
6 · The paper itself

Abstract

Melanoma is the most notorious and fatal of all skin cancers and the existing treatment options have not been proven to effectively manage this neoplasm, especially the metastatic disease. Sirtuin (SIRT) proteins have been shown to be differentially expressed in melanoma. We have shown that SIRTs 1 and 2 were overexpressed in melanoma and inhibition of SIRT1 imparts anti-proliferative responses in human melanoma cells. To elucidate the impact of SIRT 1 and/or 2 in melanoma, we created stable knockdowns of SIRTs 1, 2, and their combination using shRNA mediated RNA interference in A375 human melanoma cells. We found that SIRT1 and SIRT1&2 combination knockdown caused a decreased cellular proliferation in melanoma cells. Further, the knockdown of SIRT 1 and/or 2 resulted in a decreased colony formation in melanoma cells. To explore the downstream targets of SIRTs 1 and/or 2, we employed a label-free quantitative nano-LC-MS/MS proteomics analysis using the stable lines. We found aberrant levels of proteins involved in many vital cellular processes, including cytoskeletal organization, ribosomal activity, oxidative stress response, and angiogenesis. These findings provide clear evidence of cellular systems undergoing alterations in response to sirtuin inhibition, and have unveiled several excellent candidates for future study. SIGNIFICANCE: Melanoma is the deadliest form of skin cancer, due to its aggressive nature, metastatic potential, and a lack of sufficient treatment options for advanced disease. Therefore, detailed investigations into the molecular mechanisms of melanoma growth and progression are needed. In the search for candidate genes to serve as therapeutic targets, the sirtuins show promise as they have been found to be upregulated in melanoma and they regulate a large number of proteins involved in cellular processes known to affect tumor growth, such as DNA damage repair, cell cycle arrest, and apoptosis. In this study, we used a large-scale label-free comparative proteomics system to identify novel protein targets that are affected following knockdown of SIRT1 and/or 2 in A375 metastatic melanoma cell line. Our study offers important insight into the potential downstream targets of SIRTs 1 and/or 2. This may unravel new potential areas of exploration in melanoma research.

Indexed as

Gene Knockdown TechniquesMelanomaNeoplasm ProteinsRNA InterferenceCell Line, TumorHumansProteomicsSirtuin 1Sirtuin 2Neoplasm ProteinsSIRT1 protein, humanSIRT2 protein, humanSirtuin 1Sirtuin 2MelanomaSirtuins

Identifiers

PMID28882678
PMCPMC5673532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.